Abiopharma

News list

BIOMEA FUSION, INC. (BMEA)

SEC News
March 24, 2026, 20:09 UTC

(10% Negative) BIOMEA FUSION, INC. (BMEA) Announces Delay in data Trials for type 2 diabetes from which we expect Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

Full text

News bot March 24, 2026, 8:10 p.m.

📋 BIOMEA FUSION, INC. (BMEA) - Clinical Trial Update

Filing Date: 2026-03-24

Accepted: 2026-03-24 16:09:28

Event Type: Clinical Trial Update

Event Details:

BIOMEA FUSION, INC. (BMEA) Announces Clinical Trial Update BIOMEA FUSION, INC. (BMEA) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: data, studies
Diseases/Conditions: type 2 diabetes from which we expect
Clinical Stage: Phase I trial, Phase I
Update Type: Trial Timeline Adjustment
Primary Factors: Patient Enrollment, Regulatory Process
Collaboration: Biomea Fusion
Updated Timeline: the full year ended December 31, 2025
- anticipated in the second quarter of 2026
- anticipated in the fourth quarter of 2026
- expected in the second quarter of 2026

🔬 Clinical Development Pipeline (BIOMEA FUSION, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
BMF-650	DRUG	Phase PHASE1	Obesity	ClinicalTrials.gov
Icovamenib HPMC	DRUG	Phase PHASE1	Healthy Volunteer	ClinicalTrials.gov
BMF-500	DRUG	Phase PHASE1	Acute Myeloid Leukemia	ClinicalTrials.gov
Icovamenib	DRUG	Phase PHASE1	Healthy Volunteer	ClinicalTrials.gov
BMF-219	DRUG	Phase PHASE1	Type 2 Diabetes Mellitus	ClinicalTrials.gov

💼 Business Developments:

No business developments data available.

Structured Data:

Company Name: BIOMEA FUSION, INC.
Ticker Symbol: BMEA